Wixela Inhub Powder
NDC Package 0378-9321-32
Package Information
Wixela Inhub (fluticasone propionate and salmeterol) powders is the use of Wixela Inhub® is contraindicated in the following conditions: •Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required [see Warnings and Precautions (5.2)].•Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone propionate, salmeterol, or any of the excipients [see Warnings and Precautions (5.11), Adverse Reactions (6.3), Description (11)]. This formulation utilizes a powder delivery system. Marketed by Mylan Pharmaceuticals Inc., this product is identified by NDC 0378-9321 and is authorized under FDA application ANDA208891.
Identification & Billing
- RxCUI: 2110510 - Wixela Inhub 100/50 MCG/INHAL Dry Powder Inhaler, 60 Actuations
- RxCUI: 2110510 - 60 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler [Wixela]
- RxCUI: 2110513 - Wixela Inhub 250/50 MCG/INHAL Dry Powder Inhaler, 60 Actuations
- RxCUI: 2110513 - 60 ACTUAT fluticasone propionate 0.25 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler [Wixela]
- RxCUI: 2110516 - Wixela Inhub 500/50 MCG/INHAL Dry Powder Inhaler, 60 Actuations
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0378 - Mylan Pharmaceuticals Inc.
- 0378-9321 - Wixela Inhub
- 0378-9321-32 - 1 INHALER in 1 CARTON / 60 POWDER in 1 INHALER
- 0378-9321 - Wixela Inhub
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0378-9321-32 identifies a specific commercial package of 1 inhaler in 1 carton / 60 powder in 1 inhaler of Wixela Inhub, a human prescription drug labeled by Mylan Pharmaceuticals Inc.. This powder is formulated for respiratory (inhalation) use and contains fluticasone propionate; salmeterol xinafoate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Mylan Pharmaceuticals Inc. on February 11, 2019. The current certification is valid through December 31, 2027.
How is this Mylan Pharmaceuticals Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00378932132. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.